Review on SPARC, with data on DNA, on the protein encoded, and where the gene is implicated.
Transcription
Three transcript variants encoding different isoforms have been found for this gene.
NM_003118.3 -Homo sapiens secreted protein acidic and cysteine-rich (SPARC), transcript variant 1, mRNA: NP_003109.1. Transcript size: 3604 bp. Variant 1 encodes the predominant isoform. NM_001309443.1 -Homo sapiens secreted protein acidic and cysteine-rich (SPARC), transcript variant 2, mRNA: NP_001296372.1. Transcript size: 3601 bp. Variant 2 uses an alternate in-frame splice junction at the 5' end of an exon compared to variant 1. The resulting isoform has the same Nand C-termini but is 1 aa shorter compared to isoform 1. NM_001309444.1 -Homo sapiens secreted protein acidic and cysteine-rich (SPARC), transcript variant 3, mRNA: NP_001296373.1 . Transcript size: 3602 bp. Variant 3 uses an alternate splice junction at the 5' end of the last exon compared to variant 1 that causes a frameshift. The resulting isoform has a longer and distinct Cterminus compared to isoform 1. required for the collagen in the bone to become calcified. SPARC is also involved in extracellular matrix synthesis and remodeling being associated with the promotion of changes in cell shape. SPARC protein has been associated with tumor suppression but has also been correlated with metastasis based on changes to cell shape which can promote tumor cell invasion (GeneCard RefSeq). Molecular weight: 303aa, 43 kDa; Isoelectric point: 4.4719. Although, after cleavage of the signal sequence, SPARC is a 32-kDa protein (Mason et al. 1986) , the secreted form is identified as a 43 kDa protein on SDS-PAGE, which is due to the addition of carbohydrate (Sage et al. 1984) . NP_003109.1: molecular weight: 303 aa; NP_001296372.1: molecular weight: 302 aa; NP_001296373.1: molecular weight: 341 aa Description SPARC is a 43kDa protein, composed of 303 aminoacids. The first 17 amino acids containing the signaling peptide sequence is removed during protein processing. SPARC protein has three structural domains: N-terminal domain (NT; aa 3-51) encoded by exons 3 and 4, follistatin-like domain (FS; 53-137 aa) encoded by exons 5 and 6, the Extra Cellular domain (EC; aa 138-286) encoded by exons 7 to 9. It has eleven collagen-and six high-affinity Ca 2+ binding residues. Also, the protein presents cleavage sites for cathepsin and members of the metalloproteinases family (Brekken and Sage, 2000;  figure 1 ). The NT domain binds hydroxyapatite and calcium ions. The FS domain contains several internal disulfide bonds that stabilize two weakly interacting modules. The Nterminus region of the FS domain has a very twisted-hairpin structure that is linked by disulfide bonds at cysteines 1-3, and 2-4. This distribution of disulfide bonds makes the FS-domain structurally homologous to epidermal growth factor (EGF)-like domain of factor IX, a coagulation factor. At the other end of the FS-domain, its C-terminus region has structural similarity to Kazal family of serine proteases. It has antiparallel alpha-helices connected to small three-stranded antiparallel alpha-sheets with disulfide bonds linking cysteines 5-9, 6-8, 7-10. The EC domain contains two E-F hand motifs that bind calcium with high affinity, and comprise almost entirely of alpha-helices (Hohenester et al., 1997) .
Expression
The evaluation of the expression pattern of SPARC protein and mRNA during human embryonic and fetal development revealed that it is usually expressed in tissues undergoing rapid proliferation (Mundlos et al., 1992) . These authors also showed that earlier developmental stages showed a more general distribution, changing to more heterogeneity expression pattern in later stages. SPARC expression was observed in bone, cartilage, teeth, kidney, gonads, adrenal gland, lung, eye, vessels (Mundlos et al., 1992) . In adults SPARC is expressed in different tissues and organs, including bone marrow, whole blood, lymph node, thymus, brain, cerebellum, retina, heart, smooth muscle, skeletal muscle, spinal cord, intestine, colon, adipocyte, kidney, liver, pancreas, thyroid, salivary gland, skin, ovary, uterus, placenta, cervix and prostate (Wang et al, 2014) . 
SPARC (secreted protein acidic and cysteine-rich)
Pavanelli AC, et al. Atlas Genet Cytogenet Oncol Haematol. 2017; 21(10) It is also described that SPARC is expressed by different cell types including active osteoblasts, bone marrow progenitor cells, odontoblasts endothelial cells, fibroblasts, pericytes, astrocytes and macrophages (McCurdy et al. 2010; Rosseta and Bradshaw, 2016) . In cancer, according to PrognoScan database, SPARC expression was observed in bladder, blood, brain, breast, colorectal, eye tumors, glioma, head and neck cancer, lung, esophagus, ovarian, and skin cancer tissues (Wang et al., 2014) . There are evidences that SPARC expression is transcriptionally regulated by methylation in different types of neoplasia such as ovarian cancer (Socha et al, 2009) , pancreatic cancer (Vaz et al, 2015) , hepatocellular carcinoma (Zhang et al, 2012) colorectal (Cheetham et al., 2008) and breast (Matteucci et al, 2016) . Loss of heterozygosity (LOH) at 5q has been demonstrated in pancreatic cancer (Hahn et al., 1995) , in pulmonary fibrosis (Demopoulos et al., 2002) and myelodysplastic syndromes (Giagounidis et al., 2014) .
Localisation
SPARC is a secreted glycoprotein found mainly in the extracellular compartment. However, it has also been described to be localized both to cell nucleus and to cytoplasm (Hudson et al., 2005; Baldini et al. 2008 ).
Function
SPARC is an evolutionarily conserved matricellular glycoprotein that is involved in diverse biological processes, including tissue remodeling, wound repair, morphogenesis, cell differentiation, proliferation, migration, and angiogenesis. Matricellular glycoprotein proteins are a family of proteins that can be associated with structural elements and mediates cell-matrix interaction rather than functions as extracellular matrix (ECM) structural elements (Bornstein, 1995) . SPARC was first described in skeletal tissue as a bone-specific protein that binds selectively to both hydroxyapatite and collagen (Termine et al., 1981) . Posteriorly, it was shown that this protein is broadly expressed both in mineralized and non-mineralized tissues being associated to ECM, regulating cellmatrix interactions and cellular functions, than contributing to ECM organization (Bornstein, 2000; Bradshaw, 2012) . SPARC has also been shown to regulate the activity of matrix metalloproteinases (MMP), a family of enzymes capable of breaking down proteins, such as collagen, normally found in ECM and considered to be the mediators of ECM proteolysis and turnover. Angiogenesis, healing and metastasis, processes that require ECM restructuring are associated with higher SPARC production.
The influence of SPARC on MMP-1, MMP-3, and MMP-9 activity was first described by Tremble et al., 1993 . Further studies were carried out in transformed cells and tumor, and it was demonstrated that SPARC could increase MMP-2 activity in glioma cells and breast cancer cells but not in melanoma cells (McClung et al., 2007 , Nischt et al., 2001 , Gilles et al., 1998 .
Homology
The human SPARC gene shows 92% and 31% identity with the mouse and nematode homologs, respectively. SPARC is conserved in a wide variety of evolutionarily diverse organisms (e.g., C. elegans, Drosophila, brine shrimp, trout, chicken, mice, and humans), suggesting that it plays an important function in multicellular biology (Bradshaw and Sage, 2001 ).
Implicated in
Osteogenesis Imperfecta, Type XVII SPARC gene mutations have been correlated with a severe disease known as osteogenesis imperfecta, a connective tissue disorder characterized by low bone mass, bone fragility and susceptibility to fractures after minimal trauma. Whole-exome sequencing was carried out in 2 unrelated girls carrying osteogenesis imperfecta (OI17; 616507) leading to the identification of two different homozygous missense mutations, R166H (VAR_075142) and E263K (VAR_075143) (Mendoza-Londono et al., 2015) . Previous studies described diminished expression of SPARC in osteoblasts from patients with osteogenesis imperfecta (Muriel et al., 1991) and in osteoblasts obtained from the fro/fro mouse, an animal with fragile bones (Vetter et al., 1991) 
Osteoporosis
The involvement of SPARC in bone remodeling has been described, and its expression is observed in osteoblasts express (Kelm et al., 1992) . SPARCnull mice were reported to have decreased numbers of osteoblasts and osteoclasts, indicating decreased bone turnover, resulting in low turnover osteoporosis-like phenotype affecting trabecular bone (Delany, et al., 2000) . Also, in osteonectinnull mice, osteonectin levels have been shown to play a role in modulating the balance of bone formation and resorption in response to PTH treatment (Machado do Reis et al., 2008) .
Pulmonary and Cardiac Fibrosis
Fibrosis is characterized by excessive deposition of extracellular matrix, resulting in tissue remodeling and thus interfering with normal tissue architecture and function. Pavanelli AC, et al. Atlas Genet Cytogenet Oncol Haematol. 2017; 21(10) SPARC expression and up-regulation have been reported in multiple types of fibrosis both human and animal fibrotic models. It has been shown that SPARC can influence TGFB1 (TGF-beta), a known regulator of fibrosis. Thus it is suggested that SPARC may regulate TGF-beta activity in fibrotic tissues (Trombetta and Bradshaw, 2012) .
SPARC (secreted protein acidic and cysteine-rich)

Cardiac disease
SPARC expression was reported in cardiac disease. It is highly expressed in fibroblasts and endothelial cells and less expressed in cardiac myocytes. By screening analysis, SPARC was found as differentially expressed and potentially associated with myocardial infarction and transverse aortic constriction (Wang et al., 2015) . Also, SPARC demonstrated to have potential therapeutic applications in inhibiting cardiac dilatation and dysfunction after myocardial infarction (Schelling et al., 2009 ).
Cancer
SPARC protein modulates different cell functions like as adhesion, proliferation, angiogenesis, cell survival, and has been associated with tumor development and progression (Arnold and Brekken, 2009; Nagaraju et al., 2014) . SPARC is differentially expressed in different types of cancer, and its ability to inhibit or promote tumor progression is dependent on the cellular type, tumoral stage and the type of established interactions among the different components of cellular microenvironment (Arnold and Brekken, 2009) . The pleiotropic effects of SPARC reflect the complexity of actions of this protein, which can act as an oncogene or tumor suppressor (Podhajcer et al.,2008; Arnold and Brekken, 2009) . Hence, the role of SPARC in the process of tumorigenesis and as a tumor biomarker is still controversial. Higher levels of SPARC were observed in malignant tumors, including breast, esophagus, brain, prostate, glioma, and melanoma, suggesting that increased SPARC expression is associated with tumor progression (Framson and Sage, 2004; Bos et al.,2004; Watkins et al.,2005; Koblinski et al.,2005) . On the other hands, other studies have suggested that SPARC may act as a tumor suppressor, promoting apoptosis in ovarian cancer cells and presenting an anti-tumoral effect in pancreatic and breast cancers (Chlenski and Cohn, 2010; Nagai et al.,2011) . Tumor with high metastatic potentials such as glioblastomas, melanoma, breast and prostate cancer, express higher levels of SPARC while less metastatic tumor-like ovarian, pancreatic and colorectal tumors, expresses lower or undetectable SPARC (Feng and Tang, 2014) .
The diversity of SPARC expression effects has been observed in different types of cancers. SPARC has been associated with tumor development in melanoma, esophagus cancer, gastric cancer and glioma, and data suggests that higher expression is correlated with a more aggressive phenotype such as tumor size, metastasis and poor prognosis (Yamashita K et al., 2003; Bos et al.,2004; Framson and Sage, 2004; Wang et al., 2004; Koblinsk et al.,2005; Zhao et al., 2010; Fenouille et al., 2011; Liu et al., 2011; Rocco et al., 2011; McClung et al., 2012; Kim et al., 2013) The expression of SPARC does not seem to directly influence cellular transformation since SPARC knockout mice do not develop tumors. However, SPARC might significantly influence tumor-stroma interactions contributing to tumor progression and therapy response (Said et al., 2013) . In different tumor types such as prostatic carcinoma, neuroblastoma, pulmonary carcinoma, leukemia, pancreatic and colorectal cancer, it was described that SPARC inhibits tumor growth and reverts drug resistance increasing chemotherapy response. (Brekken et al., 2003; Sato et al., 2003; Puolakkainen et al., 2004; Said and Motamed, 2005; Tai et al., 2005; DiMartino et al., 2006; Tai and Tang, 2007; Cheetam et al., 2008; Pan et al., 2008; Wong et al., 2008; Socha et al., 2009; Bhoopathi et al., 2011; Davids and Steensma, 2010; Chew et al., 2011; Rahman et al., 2011) . Cheetham et al., 2008 , showed that the demethylating agent 5-Aza-2'deoxycytidine (5-Aza) leads to the expression of SPARC and increased chemosensitivity in colon cancer cells. In irinotecan-resistant cancer cells, endogenous or exogenous SPARC exposure triggers senescence associated with increased levels of p16 and TP53 phosphorylation (Chan et al., 2010) . Also, in vitro and in vivo studies have demonstrated that overexpression of the NT-domain of SPARC leads to a significantly greater sensitivity to chemotherapy and tumor regression that involves an interplay between the NT-domain, BCL2 and CASP8 (caspase 8), which increases apoptosis and confers greater chemosensitivity (Rahman et al., 2011) . More recently, Fan et al., demonstrated that overexpression of SPARC increased gemcitabineinduced apoptosis in pancreatic cancer cells via upregulation of the expression of apoptosis-related proteins. These findings provide insight on the role played by SPARC in drug sensitivity and that its reexpression has a potential to restore chemosensitivity.
Breast cancer
In breast cancer, SPARC is expressed in more invasive but not in non-invasive cell lines (Giles et al., 1998) . Pavanelli AC, et al. Atlas Genet Cytogenet Oncol Haematol. 2017; 21(10) In normal mammary tissue, SPARC expression was undetectable or slightly detectable and in benign mammary lesions the expression was weakly positive. However, the stromal cell of 75% of in situ and invasive breast cancer samples was strongly positive for SPARC (Bellahcène and Castronovo, 1995; Barth et al., 2005; Matteucci et al., 2016) . As previous described, the role of SPARC in breast cancer is also controversial. SPARC expression is not detected in MCF-7 breast cancer cell line, however, in response to c-Jun overexpression, SPARC expression is highly induced being associated to increased invasive and migration potential (Briggs et al., 2002) . Instead, in the tumorigenic model of breast cancer cells, MDA-MD-231, SPARC expression inhibited invasion and metastasis (Koblinski et al., 2005) . In breast tumors increased SPARC expression was associated with tumor progression and aggressiveness phenotype (Watkins et al., 2005 and Helleman et al. 2008) . On the other hand, the reduction of SPARC protein expression was associated with poor prognosis of breast cancer patients (Hsiao et al., 2010 e Nagai et al., 2011 . In breast cancer brain metastasis SPARC expression was down-regulated in comparison to primary tumors, apart from the tumoral subtype. However, among the primary tumors evaluated, triple negative subtype expressed the higher protein level (Wikman et al., 2014) . Previous data of our group, have already shown that association between SPARC and triple negative tumors, and positivity to SPARC was a marker of good prognosis in comparison to those patients with reduced SPARC level (Nagai et al., 2011) .
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